Experts break down key gynecologic cancer data and trends from the 2026 ESMO Congress.
Commentary|Articles|June 15, 2026
From Ovarian to Endometrial Cancer, Experts Spotlight Standout Data From ASCO 2026
Author(s)Caroline Seymour, Ashling Wahner
Fact checked by: Courtney Flaherty, Tracy Ann Politowicz
ASCO 2026 highlights show dostarlimab may deliver curative potential in dMMR endometrial cancer, while novel ADCs and fasting reshape ovarian care.
Advertisement
Advertisement
OncLive® connected with gynecologic oncology experts at the
Related to this article
VGX-3100 met its composite primary end point in the phase 3 HPV-303CHN trial, supporting a nonsurgical treatment approach for HPV-16/18–associated cervical HSIL.
Experts break down key kidney cancer data and trends from the 2026 ESMO Congress.
Lung cancer experts outline some of the most crucial findings from ESMO 2026 that could affect future clinical decision-making.
Rocbrutinib plus chemoimmunotherapy led to complete responses in patients with untreated B-cell lymphomas.
Sac-TMT extended survival and improved response rates vs chemotherapy in endometrial cancer that had progressed after chemotherapy and immunotherapy.
Single-agent pembrolizumab extended progression-free survival vs carboplatin and paclitaxel in mismatch repair–deficient endometrial cancer.
A post hoc analysis of SPEARHEAD-1 found that MAGE-A4 H-score was independently tied to response and progression-free survival, whereas baseline tumor burden was tied to overall survival.
Advertisement
Advertisement